A

large private insurance company and at least five state Medicaid programs are now pushing alternative epinephrine auto-injectors instead of the branded EpiPens.

Cigna, an insurance company that serves about 15 million patients, recently changed its policy: Branded EpiPen and Adrenaclick auto-injectors will no longer be covered without a “prior authorization” from the company. Additionally, in at least three states, Medicaid recipients must obtain prior approval before buying one of the brand-name auto-injectors with insurance, and in at least five states, EpiPens are only covered with a prior authorization.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy